HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.75
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.34

14 May
2024

0.060

OPEN

$1.28

4.69%

HIGH

$1.36

4,808,113

LOW

$1.27

TARGET
$1.554 16.0% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A - 0.1 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-60.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,706.9 M
Book Value Per Share xxxxxxxxxxxxxxx244.8
Net Operating Cash Flow xxxxxxxxxxxxxxx306.4 M
Net Profit Margin xxxxxxxxxxxxxxx-22.26 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-22.17 %
Return on Invested Capital xxxxxxxxxxxxxxx-11.72 %
Return on Assets xxxxxxxxxxxxxxx-9.76 %
Return on Equity xxxxxxxxxxxxxxx-22.17 %
Return on Total Capital xxxxxxxxxxxxxxx2.72 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx209.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx263 M
Long Term Debt xxxxxxxxxxxxxxx1,503 M
Total Debt xxxxxxxxxxxxxxx1,766 M
Goodwill - Gross xxxxxxxxxxxxxxx1,898 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx115 M
Price To Book Value xxxxxxxxxxxxxxx1.20

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx76.1 M
Capex % of Sales xxxxxxxxxxxxxxx4.46 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,365 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx247 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx7 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.2

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

5

xxxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

06/03/2024

5

Sell

$1.10

-17.91%

Healius has announced the immediate resignation of CEO Maxine Jacquet. Jacquet, who has been in the role just one year, will be succeeded by Paul Anderson, who has been operating as the CFO since March 2023.

With Anderson set to undertake a strategic review of the company, Citi expects the most likely outcome is the sale of the Imaging division, and that a partial sale of the Pathology department may also eventuate.

While the sale would solve near-term gearing issues, Citi expects it would not be sufficient to solve the profitability and structural challenges facing the Pathology department.

The Sell rating and target price of $1.10 are retained.

FORECAST
Citi forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.40 cents.
Citi forecasts a full year FY25 dividend of 0.00 cents and EPS of 4.40 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

HLS STOCK CHART

FNArena News on HLS

1
ESG Focus: The Little Big Things – 15-05-2024

11:00 AM - ESG Focus
2
Rudi’s View: Quality Reigns, And How To Identify It

May 01 2024 - Rudi's View
3
The Short Report – 26 Apr 2024

Apr 26 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Mar 27, 2024

Mar 27 2024 - Daily Market Reports
5
Rudi’s View: Selective Opportunities Among Discounted REITs

Mar 20 2024 - Rudi's View

Latest Healthcare services News

1
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
2
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
3
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
4
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
5
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
6
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
7
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
8
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
9
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
10
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia